Why the study?
Sudden cardiac death is responsible for approximately 10% of post-heart transplant deaths, prompting an evaluation of post-transplant SCD risk.
Do treated rejection and cardiac allograft vasculopathy increase the risk of sudden cardiac death in adult heart transplant recipients?
Do treated rejection and cardiac allograft vasculopathy increase the risk of sudden cardiac death in adult heart transplant recipients?
Severe cardiac allograft vasculopathy, graft dysfunction, and treated rejection significantly increase the risk of sudden cardiac death in heart transplant recipients.
Severe CAV with graft dysfunction or treated rejection identifies higher post-transplant SCD risk; supports risk stratification but leaves causal inference and management changes open.
Sudden cardiac death (SCD) is responsible for ~10% of post-heart transplant deaths. We conducted a retrospective analysis of the ISHLT registry evaluating the risk of post-transplant SCD. Adult heart transplant recipients (2004-2014) surviving the first year were included. We used multivariable multistate competing risk survival analysis to evaluate the impact of history of treated rejection and cardiac allograft vasculopathy (CAV) on SCD risk. We used a probabilistic analytical model and Monte Carlo simulation to estimate the impact of CAV severity and graft dysfunction on SCD. We included 25 242 recipients. During a median follow-up of 4.7 (2.3-7.0) years, 582 patients died suddenly. Treated rejection (HR 1.76, 95% CI 1.36-2.31) and CAV (HR 3.32, 95% CI 2.73-4.03) were important risk factors for SCD. The estimated SCD risk in patients with severe CAV without and with graft dysfunction was 3.2% (95% CI 2.0-4.6) and 5.4% (95% CI 3.8-7.0), respectively, at 2 years from the CAV diagnosis, and 4.9% (95% CI 3.4-6.5) and 8.0% (95% CI 6.1-10.0), respectively, in those who also had treated rejection. These results provide evidence that recipients with severe CAV and graft dysfunction or treated rejection are at clinically significant increased SCD risk. The benefit of ICD post-transplant remains uncertain.
No takes yet. Share an insight, caveat, or question.
Alba et al. (2019) studied this question.